Compounded vs Brand-Name Semaglutide: What's Actually Different?
If you have shopped for telehealth weight-loss programs, you have run into both options: brand-name semaglutide (Wegovy, Ozempic) at $1,000+ per month, and compounded semaglutide at $200–400. The active ingredient is the same molecule. Almost everything else is different.
What Semaglutide Actually Is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It mimics a hormone the gut releases after eating, which slows gastric emptying, signals satiety, and improves insulin response. Brand-name semaglutide ships in three FDA-approved forms: Ozempic (Type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral tablet, diabetes only).
Compounded semaglutide is the same active molecule prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. Compounding became widely available because the FDA placed semaglutide on its drug-shortage list in 2022 — and remained legal as long as that shortage status held. The shortage status was officially lifted in early 2025, which materially changed the legal landscape for 503A pharmacies.
The Five Differences That Matter
| Dimension | Brand-name (Wegovy/Ozempic) | Compounded |
|---|---|---|
| Manufacturer | Novo Nordisk (FDA-approved facility) | 503A or 503B compounding pharmacy |
| FDA review | Yes — full approval process | No — compounded drugs are not FDA-approved |
| Dosing format | Pre-filled pen, fixed dose increments | Vial + syringe, flexible doses |
| Typical monthly cost | $1,000–1,400 cash, ~$25 with insurance | $199–399 cash, no insurance billing |
| Quality testing | Per-batch FDA-overseen QC | Pharmacy-dependent (USP <797> minimum) |
503A vs 503B: Why The Pharmacy Designation Matters
Compounding pharmacies fall into two FDA categories. A 503A pharmacy fills patient-specific prescriptions one at a time and is regulated primarily by state boards. A 503B outsourcing facility operates under FDA Current Good Manufacturing Practice (CGMP) standards similar to a drug manufacturer, with periodic FDA inspections, batch testing, and stability data on file.
For a peptide as dose-sensitive as semaglutide, the practical implication is potency consistency and sterility assurance. A reputable provider should disclose which class of pharmacy fills its prescriptions and provide a Certificate of Analysis on request.
Is Compounded Semaglutide Safe?
The answer depends almost entirely on the pharmacy. Reputable 503B-supplied compounded semaglutide has a clean enough track record that several established medical groups now prescribe it routinely. The safety problems documented in 2023–2024 came primarily from (a) salt-form variants that the FDA had explicitly warned against, (b) overseas sources entering through grey-market resellers, and (c) under-resourced 503A pharmacies without adequate sterility infrastructure.
From a clinical standpoint, the dose math is what matters. A 1.7 mg dose of compounded semaglutide should produce the same pharmacologic effect as a 1.7 mg Wegovy injection if the active ingredient is identical and accurately measured. Independent third-party testing of major US compounders has, to date, generally confirmed potency consistency.
Which Providers Offer Each
Most established US telehealth platforms now offer at least one of these paths. The decision usually breaks down by your insurance situation and your tolerance for the FDA-approved label vs. a lower out-of-pocket cost.
Bottom Line
If your insurance covers Wegovy at a workable copay, that is the cleanest path — full FDA review, manufacturer-controlled QC, and a long real-world safety record. If you are paying cash, well-sourced compounded semaglutide from a 503B-backed provider gives you the same active molecule at a fifth of the price. The provider you pick — and the pharmacy behind it — matters more than the brand-vs-compounded distinction.